SCHEMBL16706709

SCHEMBL16706709

Cc1ccc(CN(Cc2ccc3c(c2)OCO3)Cc2nc(C(=O)NCCC(c3ccccc3)c3ccccc3)cs2)cc1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FAAH O00519 6/20 0.48
MMP1 P03956 2/20 0.43
MMP2 P08253 2/20 0.43
MMP9 P14780 2/20 0.43
MMP13 P45452 2/20 0.43
ALDH1A1 P00352 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
TSHR P16473 1/20 0.42
LMNA P02545 1/20 0.42
MAPT P10636 1/20 0.42
IDO1 P14902 1/20 0.41
HPGD P15428 1/20 0.41
MAPK1 P28482 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16706680 0.90 FAAH (0.54) FAAHMMP1MMP2MMP9MMP13
SCHEMBL16706669 0.88 MMP1 (0.45) FAAHMMP1MMP2MMP9MMP13
SCHEMBL16706793 0.88 FAAH (0.51) FAAHMMP1MMP2MMP9MMP13
SCHEMBL18427086 0.87 FAAH (0.41) FAAHMMP1MMP2MMP9MMP13
SCHEMBL16706687 0.87 MMP1 (0.45) MMP1MMP2MMP9MMP13ALDH1A1
SCHEMBL16706724 0.86 GPR55 (0.44) FAAHMMP1MMP2MMP9MMP13
SCHEMBL16706677 0.86 NPC1 (0.50) FAAHMMP1MMP2MMP9MMP13
SCHEMBL16710024 0.86 TDP1 (0.57) FAAHALDH1A1L3MBTL1MEN1KMT2A
SCHEMBL16706719 0.85 MMP13 (0.45) FAAHMMP1MMP2MMP9MMP13
SCHEMBL16706708 0.83 TAS1R3 (0.54) FAAHMMP1MMP2MMP9MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9951033-B2 Tertiary amines for use in the treatment of cardiac disorders UNIVERSITETET I OSLO (NO) 2018-04-24 US disclosed
US-9951033-B2 Tertiary amines for use in the treatment of cardiac disorders UNIVERSITETET I OSLO (NO) 2018-04-24 US disclosed
US-9556111-B2 Tertiary amines for use in the treatment of cardiac disorders UNIVERSITETET I OSLO (NO) 2017-01-31 US disclosed
US-9556111-B2 Tertiary amines for use in the treatment of cardiac disorders UNIVERSITETET I OSLO (NO) 2017-01-31 US disclosed
US-20150133510-A1 TERTIARY AMINES FOR USE IN THE TREATMENT OF CARDIAC DISORDERS UNIVERSITETET I OSLO (NO) 2015-05-14 US disclosed
US-20150133510-A1 TERTIARY AMINES FOR USE IN THE TREATMENT OF CARDIAC DISORDERS UNIVERSITETET I OSLO (NO) 2015-05-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150133510-A1 TERTIARY AMINES FOR USE IN THE TREATMENT OF CARDIAC DISORDERS TNNI3, TNNT2, MYLK2 FAAH 1670/4885MMP1 4659/4885MMP2 4326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.